Infections and antimicrobial prescribing in patients hospitalized with coronavirus disease 2019 (COVID-19) during the first pandemic wave.

Autor:	Chan L; Department of Pharmacy, Ronald Reagan UCLA Medical Center, Los Angeles, California., Gupta S; Department of Internal Medicine, Mayo Clinic Hospital, Phoenix, Arizona., Sacco AJ; Department of Pharmacy, Mayo Clinic Hospital, Phoenix, Arizona., Kasule SN; Department of Quantitative Health Sciences, Division of Clinical Trials and Biostatistics, Mayo Clinic Arizona, Scottsdale, Arizona., Chaffin H; Department of Internal Medicine, Mayo Clinic Hospital, Phoenix, Arizona., Feller FF; Division of Infectious Diseases, Yale New Haven Hospital, New Haven, Connecticut., Mi L; Department of Quantitative Health Sciences, Division of Clinical Trials and Biostatistics, Mayo Clinic Arizona, Scottsdale, Arizona., Lim ES; Department of Quantitative Health Sciences, Division of Clinical Trials and Biostatistics, Mayo Clinic Arizona, Scottsdale, Arizona., Seville MT; Division of Infectious Diseases, Mayo Clinic Hospital, Phoenix, Arizona.
Jazyk:	angličtina
Zdroj:	Antimicrobial stewardship & healthcare epidemiology : ASHE [Antimicrob Steward Healthc Epidemiol] 2023 Apr 17; Vol. 3 (1), pp. e75. Date of Electronic Publication: 2023 Apr 17 (Print Publication: 2023).
DOI:	10.1017/ash.2023.135
Abstrakt:	Objective: To evaluate the rate of coinfections and secondary infections seen in hospitalized patients with COVID-19 and antimicrobial prescribing patterns. Methods: This single-center, retrospective study included all patients aged ≥18 years admitted with COVID-19 for at least 24 hours to a 280-bed, academic, tertiary-care hospital between March 1, 2020, and August 31, 2020. Coinfections, secondary infections, and antimicrobials prescribed for these patients were collected. Results: In total, 331 patients with a confirmed diagnosis of COVID-19 were evaluated. No additional cases were identified in 281 (84.9%) patients, whereas 50 (15.1%) had at least 1 infection. In total, of 50 patients (15.1%) who were diagnosed with coinfection or secondary infection had bacteremia, pneumonia, and/or urinary tract infections. Patients who had positive cultures, who were admitted to the ICU, who required supplemental oxygen, or who were transferred from another hospital for higher level of care were more likely to have infections. The most commonly used antimicrobials were azithromycin (75.2%) and ceftriaxone (64.9%). Antimicrobials were prescribed appropriately for 55% of patients. Conclusions: Coinfection and secondary infections are common in patients who are critically ill with COVID-19 at hospital admission. Clinicians should consider starting antimicrobial therapy in critically ill patients while limiting antimicrobial use in patients who are not critically ill. Competing Interests: All authors report no conflict of interest relevant to this article. (© The Author(s) 2023.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu